Webinar: Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI by InsideScientific

Leveraging Genomic, Preclinical, and Drug Response Data in the Age of AI

About

Molecular profiling and other tumor model characterization data are becoming increasingly important to preclinical decision-making. During this presentation, you’ll experience first-hand how the latest in AI/ML tools are revolutionizing cancer research and early drug development by:

Optimizing preclinical model selection.

Informing biomarker, drug repurposing, and label expansion strategies.

Enabling quick in silico analysis of complex datasets to provide insights into therapeutic efficacy and drug response.

Simplifying data retrieval and enable efficient, ad hoc analyses for research teams.

Eligible attendees will receive access to an exciting new generative AI tool developed exclusively for cancer researchers.

Presenter

Michael Boice, PhD

Senior Director, Scientific Engagement and Key Accounts, Certis Oncology

Michael Boice, PhD, has over 20 years of experience in translational oncology drug development. Michael’s areas of scientific expertise include the development of novel oncology therapeutics, functional genomics and rare cancers. At Certis, he works directly with clients to enhance their discovery efforts through translational science discussions, optimizing the customer experience. He holds a PhD in Pharmacology from Weill Cornell Graduate School of Medical Sciences, Department of Pharmacology Memorial Sloan Kettering Cancer Center, Cancer Biology and Genetics.

First Name*

Last Name*

Email Address*

Country / Region*

Job Title*

Organization / Company*

utm_bmcr_source